Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

Linear regression of PCS score. by Le Dai Minh (14295271)

Linear regression of MCS score. by Le Dai Minh (14295271)

Parameters for linear regression. by Dania AL-Najjar (11840857)

Subjects:

Table_1_On-Farm Trials Reveal Significant but Uncertain Control of Botrytis cinerea by Aureobasidium pullulans and Potassium Bicarbonate in Organic Grapevines.DOCX by Anabelle Laurent (10185680)

“…<p>Botrytis cinerea, a fungal pathogen that causes gray mold on grapes, can decrease yield, substantially reduce wine quality, and therefore cause significant economic losses. …”

The colorimetric assay for miltefosine based on the colored complex formation with ammonium ferric thiocyanate. by Alireza Latifi (14593561)

Subjects:

General linear mixed model coefficients and significance for species-specific ungulate intensity of use as a function of cattle grazing period. by Kathryn Knodel (20036529)